Calciphylaxis in 2024
DOI:
https://doi.org/10.25796/bdd.v8i2.87068Keywords:
calciphylaxis, renal failure, dialysisAbstract
Calciphylaxis is a rare and potentially fatal disease manifested by progressive skin ulcerations due to calcification and obstruction of small-caliber arteries and arterioles. It mainly affects patients with chronic kidney disease treated by dialysis or renal transplantation but also individuals with normal kidney function, in which case it is often associated with chronic inflammatory diseases, neoplasia, primary hyperparathyroidism, and post-bariatric surgery. Necrotized ulcerations can become infected, leading to septic syndrome and a mortality rate of up to 80%. Its incidence varies from one case per 1,000 to one case per 1,500 hemodialysis patients per year, although this is probably underestimated. Clinical manifestations include very painful nodular or plaque-like indurations occurring in the extremities and central to the body. Lesions can also affect the fingers, penis, breasts, and visceral organs such as the lungs, intestines, and eyes. Its management is complex and requires a multimodal, individualized approach, involving close cooperation between nephrologists, dermatologists, surgeons, and other specialists. The aim of this review is to revise old and new aspects of this management while including the control of parameters of mineral and bone metabolism disorders, the replacement of vitamin K antagonists by alternative anticoagulants, the optimization of dialysis prescription, and the use of sodium thiosulfate, as well as new experimental therapies under development. We hope this review will help avoid common pitfalls and provide the highest quality care for patients with calciphylaxis.
References
1. Cucka B, Biglione B, Ko L, Nguyen ED, Khoury CC, Nigwekar SU, et al. Calciphylaxis arising following bariatric surgery: A case series. JAAD Case Rep. 2022;28:4-7.
2. Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133-46.
3. Xia J, Tan AJ, Biglione B, Cucka B, Ko L, Nguyen ED, et al. Nephrogenic Calciphylaxis Arising after Bariatric Surgery: A Case Series. Am J Nephrol. 2024;55(2):196-201.
4. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;379(4):399-400.
5. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122(6):1083-9; discussion 9-90.
6. Gabel CK, Nguyen ED, Chakrala T, Blum AE, Francois J, Chand S, et al. Assessment of outcomes of calciphylaxis. J Am Acad Dermatol. 2021;85(4):1057-64.
7. Nigwekar SU, Zhao S, Wenger J, Hymes JL, Maddux FW, Thadhani RI, et al. A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. J Am Soc Nephrol. 2016;27(11):3421-9.
8. Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science. 1961;134(3493):1876-7.
9. Ghosh T, Winchester DS, Davis MDP, El-Azhary R, Comfere NI. Early clinical presentations and progression of calciphylaxis. Int J Dermatol. 2017;56(8):856-61.
10. Naranjo A, Rayess N, Ryan E, Iv M, Mahajan VB. Retinal artery and vein occlusion in calciphylaxis. Am J Ophthalmol Case Rep. 2022;26:101433.
11. Ellis CL, O'Neill WC. Questionable specificity of histologic findings in calcific uremic arteriolopathy. Kidney Int. 2018;94(2):390-5.
12. Jeong HS, Dominguez AR. Calciphylaxis: Controversies in Pathogenesis, Diagnosis and Treatment. Am J Med Sci. 2016;351(2):217-27.
13. Rivet J, Lebbe C, Urena P, Cordoliani F, Martinez F, Baglin AC, et al. Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression. Arch Dermatol. 2006;142(7):900-6.
14. Dobry AS, Nguyen ED, Shah R, Mihm MC, Kroshinsky D. The role of skin biopsy in diagnosis and management of calciphylaxis: A retrospective analysis. J Am Acad Dermatol. 2021;85(3):765-7.
15. Williams EA, Moy AP, Cipriani NA, Nigwekar SU, Nazarian RM. Factors associated with false-negative pathologic diagnosis of calciphylaxis. J Cutan Pathol. 2019;46(1):16-25.
16. Mochel MC, Arakaki RY, Wang G, Kroshinsky D, Hoang MP. Cutaneous calciphylaxis: a retrospective histopathologic evaluation. Am J Dermatopathol. 2013;35(5):582-6.
17. Groover M, Nutan F. Role of bone scan in diagnosis of calciphylaxis: A review. JAAD Int. 2024;14:31-3.
18. Gupta K, Suthar PP, Bhave N, Singh JS, Venkatraman SMK, Jadhav RB. Potential Role of Bone Scintigraphy in the Diagnosis of Calciphylaxis. World J Nucl Med. 2024;23(1):3-9.
19. Paul S, Rabito CA, Vedak P, Nigwekar SU, Kroshinsky D. The Role of Bone Scintigraphy in the Diagnosis of Calciphylaxis. JAMA Dermatol. 2017;153(1):101-3.
20. Raduka J, Aggarwal A, Johnson K, Byun K, Trace AP. Bone scintigraphy findings in calciphylaxis. Radiol Case Rep. 2018;13(2):315-9.
21. Brandenburg V, Adragao T, van Dam B, Evenepoel P, Frazao JM, Ketteler M, et al. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). Clin Kidney J. 2015;8(5):567-71.
22. Gallo Marin B, Aghagoli G, Hu SL, Massoud CM, Robinson-Bostom L. Calciphylaxis and Kidney Disease: A Review. Am J Kidney Dis. 2023;81(2):232-9.
23. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580-4.
24. Nigwekar SU, Bloch DB, Nazarian RM, Vermeer C, Booth SL, Xu D, et al. Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis. J Am Soc Nephrol. 2017;28(6):1717-22.
25. Toussaint ND, Davies CE, Bongetti E, Ruderman I, Elder GJ, Hawley CM, et al. Calciphylaxis Episodes in the Australia and New Zealand Dialysis and Transplant Registry. Kidney Int Rep. 2024;9(4):951-9.
26. Fischer AH, Morris DJ. Pathogenesis of calciphylaxis: study of three cases with literature review. Hum Pathol. 1995;26(10):1055-64.
27. Rothe H, Brandenburg V, Haun M, Kollerits B, Kronenberg F, Ketteler M, et al. Ecto-5' -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients - Data from the German Calciphylaxis Registry. PLoS One. 2017;12(2):e0172407.
28. Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130(4):645-50; discussion 50-1.
29. Brandenburg VM, Kramann R, Rothe H, Kaesler N, Korbiel J, Specht P, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017;32(1):126-32.
30. Mawad HW, Sawaya BP, Sarin R, Malluche HH. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol. 1999;52(3):160-6.
31. Price PA, Williamson MK. Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J Biol Chem. 1985;260(28):14971-5.
32. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386(6620):78-81.
33. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H. Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification. FEBS Lett. 1998;433(1-2):19-22.
34. Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology (Carlton). 2006;11(5):455-61.
35. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001;21(4):274-301.
36. Caluwe R, Verbeke F, De Vriese AS. Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients. Nephrol Dial Transplant. 2020;35(1):23-33.
37. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112(3):357-66.
38. Price PA, Williamson MK, Nguyen TM, Than TN. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem. 2004;279(3):1594-600.
39. Westenfeld R, Schafer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant. 2007;22(6):1537-46.
40. Bajaj R, Courbebaisse M, Kroshinsky D, Thadhani RI, Nigwekar SU. Calciphylaxis in Patients With Normal Renal Function: A Case Series and Systematic Review. Mayo Clin Proc. 2018;93(9):1202-12.
41. Yousuf S, Busch D, Renner R, Schliep S, Erfurt-Berge C. Clinical characteristics and treatment modalities in uremic and non uremic calciphylaxis - a dermatological single-center experience. Ren Fail. 2024;46(1):2297566.
42. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007;72(2):202-7.
43. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Gladziwa U, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant. 2006;21(5):1293-9.
44. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study. Nephrol Dial Transplant. 2006;21(8):2144-51.
45. Marechal C, Schlieper G, Nguyen P, Kruger T, Coche E, Robert A, et al. Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol. 2011;6(5):974-85.
46. Wolner Z, Tello L, Kalomeris T, Swerlick R, Magro CM. Redefining Calciphylaxis as a Uniquely Bone Forming Subcutaneous C5b-9-Mediated Microvascular Injury Syndrome Associated With Localized Subcutaneous and Systemic Complement Pathway Activation. Am J Dermatopathol. 2024;46(12):807-18.
47. Anderson M, Magro C, Belmont HM. Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study. Lupus Sci Med. 2023;10(2).
48. Magro CM, Momtahen S, Mulvey JJ, Yassin AH, Kaplan RB, Laurence JC. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol. 2015;37(5):349-56; quiz 57-9.
49. Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis. Kidney Int Rep. 2019;4(2):231-44.
50. Wen W, Portales-Castillo I, Seethapathy R, Krinsky S, Kroshinsky D, Kalim S, et al. Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients - a systematic review and meta-analysis. Nephrol Dial Transplant. 2022.
51. Harris C, Kiaii M, Lau W, Farah M. Multi-intervention management of calcific uremic arteriolopathy in 24 patients. Clin Kidney J. 2018;11(5):704-9.
52. McCarthy JT, El-Azhary RA, Patzelt MT, Weaver AL, Albright RC, Bridges AD, et al. Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. Mayo Clin Proc. 2016;91(10):1384-94.
53. Chinnadurai R, Sinha S, Lowney AC, Miller M. Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians. BMC Nephrol. 2020;21(1):403.
54. Green JA, Green CR, Minott SD. Calciphylaxis treated with neurolytic lumbar sympathetic block: case report and review of the literature. Reg Anesth Pain Med. 2000;25(3):310-2.
55. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol. 2002;15(6):676-80.
56. National Kidney F. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis. 2015;66(5):884-930.
57. Adapa S, Naramala S, Gayam V, Koduri NM, Daggubati SR, Patel P, et al. Calciphylaxis in a Patient on Home Hemodialysis. J Investig Med High Impact Case Rep. 2020;8:2324709620922718.
58. Baldwin C, Farah M, Leung M, Taylor P, Werb R, Kiaii M, et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis. 2011;58(6):988-91.
59. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017;92(1):26-36.
60. Nordheim E, Dahle DO, Syse IM, Asberg A, Reisaeter AV, Hartmann A. Resolution of Calciphylaxis After Urgent Kidney Transplantation in 3 Patients With End-Stage Kidney Failure. Transplant Direct. 2016;2(11):e113.
61. Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ. Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant. 2008;23(1):387-9.
62. Sharma A, Burkitt-Wright E, Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol. 2006;155(6):1295-7.
63. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827-35.
64. Chertow GM, Parfrey PS. Cinacalcet for cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2013;368(19):1844-5.
65. Torregrosa JV, Duran CE, Barros X, Blasco M, Arias M, Cases A, et al. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia. 2012;32(3):329-34.
66. Torregrosa JV, Sanchez-Escuredo A, Barros X, Blasco M, Campistol JM. Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates. Clin Nephrol. 2015;83(4):231-4.
67. Kodumudi V, Jeha GM, Mydlo N, Kaye AD. Management of Cutaneous Calciphylaxis. Adv Ther. 2020;37(12):4797-807.
68. Tominaga A, Wada K, Kato Y, Okazaki K. Course and treatment of severe osteoporosis complicated by calciphylaxis: a case report. JBMR Plus. 2025;9(1):ziae154.
69. Hayden MR, Goldsmith D, Sowers JR, Khanna R. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol. 2008;40(2):443-51.
70. Vedvyas C, Winterfield LS, Vleugels RA. Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol. 2012;67(6):e253-60.
71. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E, Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8(7):1162-70.
72. Zitt E, Konig M, Vychytil A, Auinger M, Wallner M, Lingenhel G, et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant. 2013;28(5):1232-40.
73. Lu Y, Shen L, Zhou L, Xu D. Success of small-dose fractionated sodium thiosulfate in the treatment of calciphylaxis in a peritoneal dialysis patient. BMC Nephrol. 2022;23(1):4.
74. Gossett C, Suppadungsuk S, Krisanapan P, Tangpanithandee S, Thongprayoon C, Mao MA, et al. Sodium Thiosulfate for Calciphylaxis Treatment in Patients on Peritoneal Dialysis: A Systematic Review. Medicina (Kaunas). 2023;59(7).
75. AlBugami MM, Wilson JA, Clarke JR, Soroka SD. Oral sodium thiosulfate as maintenance therapy for calcific uremic arteriolopathy: a case series. Am J Nephrol. 2013;37(2):104-9.
76. Strazzula L, Nigwekar SU, Steele D, Tsiaras W, Sise M, Bis S, et al. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013;149(8):946-9.
77. Wajih Z, Singer R. Successful treatment of calciphylaxis with vitamin K in a patient on haemodialysis. Clin Kidney J. 2022;15(2):354-6.
78. Neofytou IE, Stamou A, Demopoulos A, Roumeliotis S, Zebekakis P, Liakopoulos V, et al. Vitamin K for Vascular Calcification in Kidney Patients: Still Alive and Kicking, but Still a Lot to Learn. Nutrients. 2024;16(12).
79. Klingel R, Fassbender C, Fassbender T, Erdtracht B, Berrouschot J. Rheopheresis: rheologic, functional, and structural aspects. Ther Apher. 2000;4(5):348-57.
80. Toksvang LN, Berg RM. Using a classic paper by Robin Fahraeus and Torsten Lindqvist to teach basic hemorheology. Adv Physiol Educ. 2013;37(2):129-33.
81. Tsurumi-Ikeya Y, Tamura K, Azuma K, Mitsuhashi H, Wakui H, Nakazawa I, et al. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients. Arterioscler Thromb Vasc Biol. 2010;30(5):1058-65.
82. Nakamura T, Ushiyama C, Osada S, Inoue T, Shimada N, Koide H. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. J Diabetes Complications. 2003;17(6):349-54.
83. Bouderlique E, Provot F, Lionet A. Rheopheresis for Adjuvant Treatment in Resistant Calciphylaxis. Ther Apher Dial. 2018;22(4):413-4.
84. Naciri Bennani H, Jouve T, Boudjemaa S, Gil H, Rostaing L. Hemodialysis coupled with rheopheresis in calciphylaxis: A winning combination. J Clin Apher. 2019;34(5):631-3.
85. Robert T, Lionet A, Bataille S, Seret G. Rheopheresis: A new therapeutic approach in severe calciphylaxis. Nephrology (Carlton). 2020;25(4):298-304.
86. Ferrer MD, Ketteler M, Tur F, Tur E, Isern B, Salcedo C, et al. Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification. PLoS One. 2018;13(5):e0197061.
87. Perello J, Joubert PH, Ferrer MD, Canals AZ, Sinha S, Salcedo C. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. Br J Clin Pharmacol. 2018;84(12):2867-76.
88. Raggi P, Bellasi A, Sinha S, Bover J, Rodriguez M, Ketteler M, et al. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial. Kidney Int Rep. 2020;5(12):2178-82.
89. Sinha S, Nigwekar SU, Brandenburg V, Gould LJ, Serena TE, Moe SM, et al. Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension. EClinicalMedicine. 2024;75:102784.
90. Seethapathy H, Noureddine L. Calciphylaxis: Approach to Diagnosis and Management. Adv Chronic Kidney Dis. 2019;26(6):484-90.
91. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210-7.
92. Sillero-Herrera A, Gomez-Herreros R, Vergara-Lopez S. Calciphylaxis. N Engl J Med. 2018;379(4):398-9.
93. el-Azhary RA, Arthur AK, Davis MD, McEvoy MT, Gibson LE, Weaver AL, et al. Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis. JAMA Dermatol. 2013;149(1):63-7.
94. Darres A, Delaval R, Fournier A, Tournier E, Cointault O, Moussion F, et al. The Effectiveness of Topical Cerium Nitrate-Silver Sulfadiazine Application on Overall Outcome in Patients with Calciphylaxis. Dermatology. 2019;235(2):120-9.
95. Lopez Martinez JA, Rodriguez Valiente M, Fuente-Mora C, Garcia-Hernandez AM, Canovas Sanchis S, Fernandez Pascual CJ. Use of cryopreserved human amniotic membrane in the treatment of skin ulcers secondary to calciphylaxis. Dermatol Ther. 2021;34(2):e14769.
96. Cai MM, Smith ER, Brumby C, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particle levels can be reduced by dialysis, sodium thiosulphate and plasma exchange. Potential therapeutic implications for calciphylaxis? Nephrology (Carlton). 2013;18(11):724-7.
97. Siami GA, Siami FS. Intensive tandem cryofiltration apheresis and hemodialysis to treat a patient with severe calciphylaxis, cryoglobulinemia, and end-stage renal disease. ASAIO J. 1999;45(3):229-33.
98. Tittelbach J, Graefe T, Wollina U. Painful ulcers in calciphylaxis - combined treatment with maggot therapy and oral pentoxyfillin. J Dermatolog Treat. 2001;12(4):211-4.
Full Text
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pablo Antonio Ureña Torres
This work is licensed under a Creative Commons Attribution 4.0 International License.
